Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.
2.

Laboratory surveillance of invasive pneumococcal disease in Australia in 2001 to 2002--implications for vaccine serotype coverage.

Watson M, Bayley K, Bell JM, Gilbert GL, Hogg G, Keil AD, Krause V, Murphy D, Roche P, Smith HV, Stewart MG, Stylianopoulos J, Turnidge J.

Commun Dis Intell Q Rep. 2003;27(4):478-87.

3.

Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.

Watson M, Roche P, Bayley K, Bell JM, Collignon P, Gilbert GL, Hogg G, Keil AD, Krause V, Murphy D, Smith HV, Brown M, Stylianopoulos J, Turnidge J.

Commun Dis Intell Q Rep. 2004;28(4):455-64.

4.

Serotypes/groups distribution and antimicrobial resistance of invasive pneumococcal isolates: implications for vaccine strategies.

Kyaw MH, Clarke S, Edwards GF, Jones IG, Campbell H.

Epidemiol Infect. 2000 Dec;125(3):561-72.

5.
6.
7.

Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Apr;300(4):237-47. doi: 10.1016/j.ijmm.2009.05.005. Epub 2009 Jul 14.

PMID:
19604721
8.

High nasopharyngeal carriage of non-vaccine serotypes in Western Australian aboriginal people following 10 years of pneumococcal conjugate vaccination.

Collins DA, Hoskins A, Bowman J, Jones J, Stemberger NA, Richmond PC, Leach AJ, Lehmann D.

PLoS One. 2013 Dec 3;8(12):e82280. doi: 10.1371/journal.pone.0082280. eCollection 2013.

9.

Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.

Hanna-Wakim R, Chehab H, Mahfouz I, Nassar F, Baroud M, Shehab M, Pimentel G, Wasfy M, House B, Araj G, Matar G, Dbaibo G; Lebanese Inter-Hospital Pneumococcal Surveillance Program.

Vaccine. 2012 Dec 31;30 Suppl 6:G11-7. doi: 10.1016/j.vaccine.2012.07.020.

PMID:
23228352
10.

Pneumococcal bacteraemia in Belgium (1994 2004): the pre-conjugate vaccine era.

Flamaing J, Verhaegen J, Vandeven J, Verbiest N, Peetermans WE.

J Antimicrob Chemother. 2008 Jan;61(1):143-9. Epub 2007 Nov 13.

PMID:
17999974
11.

Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study.

Charfi F, Smaoui H, Kechrid A.

Vaccine. 2012 Dec 31;30 Suppl 6:G18-24. doi: 10.1016/j.vaccine.2012.07.017.

PMID:
23228353
12.

Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.

Nakano S, Fujisawa T, Ito Y, Chang B, Suga S, Noguchi T, Yamamoto M, Matsumura Y, Nagao M, Takakura S, Ohnishi M, Ihara T, Ichiyama S.

Vaccine. 2016 Jan 2;34(1):67-76. doi: 10.1016/j.vaccine.2015.11.015. Epub 2015 Nov 19.

13.

Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates from 17 Chinese cities from 2011 to 2016.

Zhao C, Li Z, Zhang F, Zhang X, Ji P, Zeng J, Hu B, Hu Z, Liao K, Sun H, Zhang R, Cao B, Zhuo C, Jia W, Mei Y, Chu Y, Xu X, Yang Q, Jin Y, Fu Q, Xu X, Li H, Wang L, Ni Y, Liang H, Wang H.

BMC Infect Dis. 2017 Dec 29;17(1):804. doi: 10.1186/s12879-017-2880-0.

14.

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Japan after introduction of the routine immunization program.

Miyazaki H, Shibuya R, Midorikawa N, Chang B, Ohnishi M, Matsumoto T.

J Infect Chemother. 2017 Apr;23(4):234-240. doi: 10.1016/j.jiac.2016.12.016. Epub 2017 Feb 1.

PMID:
28161295
15.

Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010.

Kobayashi M, Conklin LM, Bigogo G, Jagero G, Hampton L, Fleming-Dutra KE, Junghae M, Carvalho MD, Pimenta F, Beall B, Taylor T, Laserson KF, Vulule J, Van Beneden C, Kim L, Feikin DR, Whitney CG, Breiman RF.

BMC Infect Dis. 2017 Jan 5;17(1):25. doi: 10.1186/s12879-016-2103-0.

16.

Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive Streptococcus pneumoniae isolates after implementation of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Bulgaria.

Setchanova L, Murdjeva M, Stancheva I, Alexandrova A, Sredkova M, Stoeva T, Yoneva M, Kurchatova A, Mitov I.

Braz J Infect Dis. 2017 Jul - Aug;21(4):433-440. doi: 10.1016/j.bjid.2017.03.011. Epub 2017 May 1.

17.

Antibiotic susceptibility rates of invasive pneumococci before and after the introduction of pneumococcal conjugate vaccination in Germany.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2015 Oct;305(7):776-83. doi: 10.1016/j.ijmm.2015.08.031. Epub 2015 Aug 22.

PMID:
26324014
18.

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study.

Miller E, Andrews NJ, Waight PA, Slack MP, George RC.

Lancet Infect Dis. 2011 Oct;11(10):760-8. doi: 10.1016/S1473-3099(11)70090-1. Epub 2011 May 27.

PMID:
21621466
19.

Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines.

Mokaddas E, Albert MJ.

Expert Rev Vaccines. 2016 Oct;15(10):1337-45. doi: 10.1080/14760584.2016.1198698. Epub 2016 Jun 24.

PMID:
27267070
20.

Supplemental Content

Support Center